drugset / Trial / NCT00410592

Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

NCT00410592 ↗

Phase 4 Completed 90 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

This study will be conducted in order to determine safety and efficacy esomeprazole, lansoprazole and pantoprazole control stomach acid by measuring the stomach acid in men and women of Hispanic origin who have GERD.

Timeline

Start
2006-10
Primary completion
—
Completion
2007-05

Outcome

Met primary endpoint

paper Esomeprazole suppressed intragastric acid (pH >4.0) significantly longer over 24 h (primary end point) compared with lansoprazole and pantoprazole (P < 0.0001) PMID 20456300 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg Oral
Subject Lansoprazole Other / unclassified 30 mg Oral
Subject Pantoprazole Other / unclassified 40 mg Oral